Sweden
# |
Name |
Net Income Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
38.87%
|
Dec. 31, 2023 | USD 2.25 | -17.68% |
|
Sweden |
|
2 |
37.22%
|
Dec. 31, 2023 | USD 18.98 | -4.07% |
|
Sweden |
|
3 |
25.13%
|
Dec. 31, 2023 | USD 52.33 | -2.11% |
|
Sweden |
|
4 |
20.94%
|
Dec. 31, 2024 | USD 41.47 | -0.80% |
|
Sweden |
|
5 |
19.54%
|
Dec. 31, 2023 | USD 3.64 | -2.31% |
|
Sweden |
|
6 |
19.24%
|
Dec. 31, 2023 | USD 19.20 | -5.48% |
|
Sweden |
|
7 |
10.89%
|
Dec. 31, 2023 | USD 29.22 | -3.00% |
|
Sweden |
|
8 |
9.04%
|
Dec. 31, 2023 | USD 20.58 | -5.59% |
|
Sweden |
|
9 |
7.54%
|
Dec. 31, 2023 | USD 0.21 | -4.72% |
|
Sweden |
|
10 |
7.14%
|
Dec. 31, 2023 | USD 2.77 | -4.78% |
|
Sweden |
|
11 |
4.60%
|
Dec. 31, 2023 | USD 2.53 | -0.42% |
|
Sweden |
|
12 |
4.41%
|
Dec. 31, 2024 | USD 3.53 | -1.01% |
|
Sweden |
|
13 |
4.37%
|
Dec. 31, 2023 | USD 0.79 | -7.19% |
|
Sweden |
|
14 |
3.42%
|
Dec. 31, 2023 | USD 8.44 | 1.06% |
|
Sweden |
|
15 |
2.97%
|
Dec. 31, 2023 | USD 3.55 | -2.70% |
|
Sweden |
|
16 |
2.18%
|
Dec. 31, 2023 | USD 4.60 | 0.04% |
|
Sweden |
|
17 |
1.96%
|
Dec. 31, 2023 | USD 13.28 | -2.29% |
|
Sweden |
|
18 |
1.82%
|
Dec. 31, 2023 | USD 3.19 | -1.80% |
|
Sweden |
|
19 |
1.01%
|
Dec. 31, 2023 | USD 18.49 | 0.08% |
|
Sweden |
|
20 |
0.73%
|
Dec. 31, 2023 | USD 0.22 | -4.95% |
|
Sweden |
|
21 |
-0.87%
|
Dec. 31, 2023 | USD 0.14 | 2.05% |
|
Sweden |
|
22 |
-7.23%
|
Dec. 31, 2023 | USD 0.81 | -4.47% |
|
Sweden |
|
23 |
-13.09%
|
Dec. 31, 2023 | USD 0.27 | -2.38% |
|
Sweden |
|
24 |
-20.08%
|
Dec. 31, 2023 | USD 1.64 | -3.31% |
|
Sweden |
|
25 |
-21.70%
|
Dec. 31, 2023 | USD 0.16 | -2.74% |
|
Sweden |
|
26 |
-24.24%
|
April 30, 2024 | USD 0.13 | -1.11% |
|
Sweden |
|
27 |
-38.74%
|
Dec. 31, 2023 | USD 1.59 | -2.74% |
|
Sweden |
|
28 |
-97.69%
|
Dec. 31, 2023 | USD 0.13 | 0.88% |
|
Sweden |
|
29 |
-109.65%
|
Dec. 31, 2023 | USD 19.80 | -1.20% |
|
Sweden |
|
30 |
-146.02%
|
Dec. 31, 2023 | USD 0.31 | 1.24% |
|
Sweden |
|
31 |
-161.97%
|
Dec. 31, 2023 | USD 0.84 | -2.95% |
|
Sweden |
|
32 |
-356.72%
|
Dec. 31, 2023 | USD 0.71 | 8.98% |
|
Sweden |
|
33 |
-375.20%
|
Dec. 31, 2023 | USD 0.50 | -2.16% |
|
Sweden |
|
34 |
-393.45%
|
Aug. 31, 2024 | USD 0.26 | 0.92% |
|
Sweden |
|
35 |
-462.22%
|
Dec. 31, 2023 | USD 2.43 | -5.44% |
|
Sweden |
|
36 |
-567.53%
|
Dec. 31, 2023 | USD 0.54 | -2.24% |
|
Sweden |
|
37 |
-620.25%
|
Dec. 31, 2023 | USD 3.01 | -2.55% |
|
Sweden |
|
38 |
-643.30%
|
Dec. 31, 2023 | USD 0.21 | 1.47% |
|
Sweden |
|
39 |
-648.37%
|
Dec. 31, 2023 | USD 0.39 | -4.99% |
|
Sweden |
|
40 |
-678.73%
|
Dec. 31, 2023 | USD 0.38 | -3.14% |
|
Sweden |
|
41 |
-707.30%
|
Dec. 31, 2023 | USD 0.16 | 9.53% |
|
Sweden |
|
42 |
-747.38%
|
Dec. 31, 2023 | USD 0.09 | -2.04% |
|
Sweden |
|
43 |
-1,283.24%
|
Dec. 31, 2023 | USD 0.09 | 11.18% |
|
Sweden |
|
44 |
-1,712.25%
|
April 30, 2024 | USD 0.18 | -8.41% |
|
Sweden |
|
45 |
-3,132.07%
|
Dec. 31, 2023 | USD 1.30 | -5.64% |
|
Sweden |
|
46 |
-5,208.39%
|
Dec. 31, 2023 | USD 0.19 | -8.49% |
|
Sweden |
|
47 |
-6,103.70%
|
Dec. 31, 2023 | USD 0.25 | -3.82% |
|
Sweden |
|
48 |
-6,269.47%
|
Dec. 31, 2023 | USD 0.09 | -2.98% |
|
Sweden |
|
49 |
-6,427.99%
|
Dec. 31, 2023 | USD 0.18 | -3.03% |
|
Sweden |
|
50 |
-70,147.17%
|
Dec. 31, 2023 | USD 1.25 | -0.41% |
|
Sweden |
The Healthcare company in Sweden with the highest Net Income Margin is Genovis AB (publ.) (Stockholm Stock Exchange: GENO.ST) at 38.87%.
The Healthcare company in Sweden with the lowest Net Income Margin is OncoZenge AB (publ) (Stockholm Stock Exchange: ONCOZ.ST) at -530,066.67%.
The top 10 Healthcare companies in Sweden by Net Income Margin are Genovis AB (publ.), BioArctic AB (publ), Camurus AB (publ), Xvivo Perfusion AB (publ), Sleep Cycle AB (publ), CellaVision AB (publ), Swedish Orphan Biovitrum AB (publ), Stille AB, ADDvise Group AB (publ) and Magle Chemoswed Holding AB (publ).
The bottom 10 Healthcare companies in Sweden by Net Income Margin are OncoZenge AB (publ), Diamyd Medical AB (publ), Lipum AB (publ), SpectraCure AB (publ), Kancera AB (publ), Alzinova AB (publ), Nanologica AB (publ), IRLAB Therapeutics AB (publ), Biovica International AB (publ) and Intervacc AB (publ).